UVLrx™ European Launch: Targeting 14th Annual Aesthetic & Anti-Aging Medicine World Congress
After a successful North American debut last month at the American Academy of Anti-Aging Medicine (A4M) in Las Vegas, UVLrx Therapeutics™ is pleased to announce the official European launch of its intravenous light therapy treatment system, the model UVL1500, at this year’s 14th Aesthetic & Anti-Aging Medicine World Congress (AMWC) from March 31st to April 2nd. Under the scientific supervision of the World Society of Interdisciplinary Anti-Aging Medicine (WOSIAM), the conference will attract over 10,000 physicians and researchers from more than 120 countries who are interested in the role of prevention in global aesthetic and anti-aging management. At the Congress, UVLrx Therapeutics™ will highlight the clinically proven benefits of light wavelengths utilized by its UVLrx™ Treatment System* for reducing inflammation, a key issue facing the entire $300 billion global industry today.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160120006185/en/
The UVLrx Station™ Model UVL1500 offers the first intravenous, concurrent delivery of ultraviolet-A (UVA) and multiple visible light wavelengths for treating a variety of medical indications. Using the company’s patent-pending Dry Light Adapter™ and a standard IV catheter, the device treats blood intravenously, thus eliminating the need for removal of blood from the body. (Photo: Business Wire)
“Inflammation is a common side effect of all aesthetic procedures, whether they be facial laser treatments, injections or surgery,” said Michael Harter, CEO and president of UVLrx. “By immediately reducing inflammation caused by an aesthetic procedure, our technology will minimize pain and accelerate healing, which in turn will lead to better results and a more satisfied post-op patient.”
“Beyond aesthetic procedures, chronic inflammation can occur due to pathogens in the bloodstream and just everyday stress,” commented Rowland Hanson, chairman of UVLrx. “Left untreated, chronic inflammation accelerates the aging process and has been linked to heart disease, cancer and Alzheimer’s disease. This is why UVLrx is an essential adjunct therapy for physicians practicing both aesthetic and anti-aging medicine.”
In addition to its exhibitor booth at the Congress, UVLrx has secured an adjacent private salon for physician and distributor on-site demonstrations of its CE-marked UVLrx Station™ Model UVL1500. Moreover, UVLrx Chief Science Officer, Ryan Maloney, has been asked to speak at a special session at noon on Friday, April 1st, about the efficacy of ultraviolet light and UVLrx technology for both anti-aging and aesthetics purposes. To ensure that Congress attendees are aware of UVLrx Therapeutics’ participation at AMWC, the company has secured inside front cover advertising, as well as a two-page promotional article, in the March/April issue of PRIME Journal, which will be distributed to all Congress attendees as well as the publication’s nearly 100,000 additional print and online subscribers.
“We look forward to sharing our technology with the global aesthetics and anti-aging community at AMWC 2016 and demonstrating, in person, how the UVLrx Treatment System will benefit all physicians practicing in this field,” added UVLrx CSO Ryan Maloney. “We are especially excited that the theme of the Congress this year is prevention, given the clinically proven ability of the wavelengths utilized by the UVLrx Station™ to immediately reduce inflammation caused by such things as pathogens in the bloodstream, stress and a wide range of aesthetic surgical procedures.”
Ultraviolet blood irradiation (UBI) has been used for over a century to treat bacterial and viral infections and was awarded a Nobel Prize for treating lupus in 1903. Routinely used in hospitals around the world, this form of light therapy fell out of prominence in the U.S. with the advent of antibiotics in the 1950s. With the recent expansion of drug-resistant infections, blood irradiation offers significant advantages to pharmaceutical therapies. Furthermore, UVLrx’s intravenous system is superior to existing ultraviolet blood irradiation (UBI) in that it does not require removal of blood from the body.
To learn more, visit UVLrx.com and stop by the UVLrx Therapeutics booth (F18) at the Congress. Also be sure to attend the lecture “The Must of Detoxification” in Room Auric between 12:00 and 13:00 on Friday, April 1st, to hear from UVLrx Chief Scientist Ryan Maloney.
The UVLrx Station™ Model UVL1500 is not available for sale in the U.S.
* References to published specific wavelength studies available upon request.
About UVLrx Therapeutics
Based in Oldsmar, Florida, UVLrx Therapeutics is dedicated to evidence-based medicine in the field of light therapy and offers the first intravenous, concurrent delivery of ultraviolet-A (UVA) and multiple visible light wavelengths for treating a variety of medical indications. In addition to two Nobel Prizes and NASA-backed research, hundreds of international clinical trials have verified the health benefits of UV and other wavelengths of light utilized in the UVLrx™ Treatment System. For more information, please visit http://uvlrx.com.
About EuroMediCom (organizer of AMWC)
Based in Paris, France, EuroMediCom was co-founded by Catherine Decuyper and Christophe Luino. It is the official organizer of the Aesthetic & Anti-Aging Medicine World Congress (AMWC). This Congress has been launched with a strong belief that effective aging prevention and treatment must be comprehensively addressed integrating two aspects: using aesthetics strategy (dermatology and surgery) for the external appearance, and applying anti-aging medicine for internal well-being. EuroMediCom is not only present in Europe but also partner of many other major congresses in the rest of the world. Since the development of anti-aging medicine, EuroMediCom took an important part in the creation of the first world premier European University Master Program in Preventive, Regenerative and Anti-aging Medicine, recognized today as the best program in the field with an official delivered master degree by the Dresden International University. For more information, please visit http://v1.euromedicom.com/amwc-2016/index.html.
About the World Society of Interdisciplinary Anti-Aging Medicine (WOSIAM)
Based in Paris, France, the World Society of Interdisciplinary Aesthetic and Anti-Aging Medicine (WOSIAM) has quickly become the world's fastest growing anti-aging medicine society to federate international physicians and scientific societies. The main goal of this nonprofit organization is to promote anti-aging medicine through research and educational events for physicians and the general public. The society is predominantly formed by and for physicians. It is the belief of the society's board of directors that the best way for anti-aging medicine to advance is by the endorsement of medical doctors competent in administering safe, evidenced-based anti-aging therapeutics. For more information, please visit http://www.wosiam.org.
About the American Academy of Anti-Aging Medicine (A4M)
Based in Boca Raton, Florida, A4M is a leading nonprofit medical society dedicated to the detection, prevention and treatment of age-related diseases. Dedicated to educating physicians, scientists and the public on biomedical sciences, breaking technologies and preventative medicine issues, the A4M is comprised of over 26,000 members from 120 nations worldwide, including healthcare practitioners, scientists, researchers and governmental officials. For more information, see http://www.a4m.com.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
FCF: Greenpeace Allegations Unfair and Deceptive26.5.2018 18:02 | Pressemelding
FCF Fishery, Co. President Max Chou today released the following statement regarding recent misleading Greenpeace human rights abuse allegations made against the company: “We realize that as one of the world’s largest marine products integrated supply chain service providers with more than 30 subsidiaries, fishing bases, and shipping agents around the world, we are a prime target for organizations seeking to garner publicity and those not fully aware of the latest development and improvements that are currently taking place in the fishery industry. However, in their efforts to curb egregious human rights abuses, we believe it is unfair and deceptive to lump our company in with those who condone cruelty and neglect of their laborers. “Although we recognize the meaningful work of Greenpeace in exposing and eliminating human trafficking and sustainability abuses, we are equally disappointed that they are implicating FCF in old incidents and cases that have since been in all instances addr
NBC Universal, Havas Group and Endemol Shine Discuss a Future with AI, Blockchain and VR at IBC201825.5.2018 18:20 | Pressemelding
As is fitting for the home of technical invention and innovation, IBC2018 will present a broad range of ambitious and timely elements to engage, inform and inspire content creators and owners from around the world that will visit the RAI, Amsterdam from 13-18 September 2018. The must-attend event includes fresh inspiring conference themes that will focus on innovative new platforms, audience engagement and interaction/immersion, as well as a wide-ranging exhibition that will encompass all the latest technologies from AI and VR to advanced cloud-based workflows. Registration for IBC2018 is now open at: https://ibc.itnint.com/IBC18/Online/RegLogin.aspx “The media landscape is evolving at an unprecedented rate, with new platforms, technologies and even new realities at our disposal that offer greater opportunities for content innovation and audience engagement,” said Michael Crimp, CEO, IBC. “IBC is preparing an outstanding programme of conference sessions, forums and exhibition features
Pavilion of France at the 16th International Architecture Exhibition – La Biennale di Venezia25.5.2018 09:26 | Pressemelding
The concept for Infinite Places , developed by the Encore Heureux team, led by the architects Nicola Delon, Julien Choppin, and Sébastien Eymard, presents places produced by new and inventive processes that generate architectural processes of value. This exhibition project, which considers the territory as a whole, highlights initiatives on the part of civil society and communities that embody a certain free spirit of experimentation and the possibilities opened up by architecture. These projects are expressions of programmatic freedom and generosity, and they live up to the theme of Freespace adopted by the two commissioners of the 16th International Architecture Exhibition – La Biennale di Venezia, the Irish architects Yvonne Farrell and Shelly McNamara. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180525005191/en/ French Pavilion Venice Architectural Biennale, copyright S. Scher Statement of the curators « Through the I
SIA Acquires Card Processing Businesses in Central and Southeastern Europe from First Data25.5.2018 08:30 | Pressemelding
SIA, a European high-tech leader in payment infrastructure and services, and First Data Corporation (NYSE: FDC), a global leader in commerce-enabling technology, have signed an agreement for SIA to acquire First Data’s card processing businesses in parts of Central and Southeastern Europe for €375 million. In 2017, these businesses generated a combined revenue of approximately €100 million for First Data. This acquisition by SIA provides card processing, card production, call center and back-office services, including 13.3 million payment cards, 1.4 billion transactions, in addition to the management of POS terminals and ATMs. These businesses are primarily located in 7 countries: Greece, Croatia, Czech Republic, Hungary, Romania, Serbia and Slovakia. As a result of the transaction, SIA will become a leading player in processing and services in the region. The agreement includes the transfer of about 1,400 First Data employees into SIA. “This acquisition is in line with our strategy to
Westinghouse Accident Tolerant Fuel Development Moves Forward with Cooperation Agreement with ENUSA25.5.2018 06:00 | Pressemelding
Westinghouse Electric Company today announced that it will collaborate in the development of its EnCore® Fuel, the revolutionary accident-tolerant fuel (ATF) design, with ENUSA Industrias Avanzadas (ENUSA) through a Frame Cooperation Agreement (FCA). “This agreement serves to strengthen the technical and commercial relations between ENUSA and Westinghouse as we work to develop leading nuclear fuel technology,” said Torbjörn Norén, European Fuel Group and EMEA Fuel Delivery Director at Westinghouse. “Westinghouse’s work with ENUSA in the Spanish and European Fuel Group markets will help to facilitate agreements with customers to launch EnCore Fuel demonstration programs in their plants.” Under the terms of the agreement, the newly signed FCA establishes the framework that will regulate the different Joint Development Programs (JDPs) to be launched between both companies. The first JDP will evaluate the application of the segmented rod concept and develop models of ATF / EnCore fuel beha
BRIC HOLDING Offers Aimedis – ICO: Germany’s Leading eHealth Platform Goes Public25.5.2018 06:00 | Pressemelding
Since Wednesday, May 16, investors finally have a chance to claim their share of a unique success story, the international market roll-out of Aimedis, by purchasing AIM tokens: AIM tokens are now available with a 20% presale bonus PLUS a 5% early bird-premium only at the Czech investment house BRIC INVEST https://www.bric-holding.com/home_en.html! Aimedis aims to shape the future of healthcare by providing an advanced and fully operational platform, secured by blockchain and supported by AI, that enables patients to take control, secure the exchange of their medical data, access the best healthcare providers, get advice, prescriptions, personal health upgrades and to become part of the health revolution. And we are not talking about the future: The revolutionary Aimedis platform is already deployed as a live working system and is already in use in major hospital groups in Germany! By issuing 300 million AIM tokens at a nominal value of 0,12 USD each, the Aimedis consortium will raise c